1. Home
  2. KODK vs AKBA Comparison

KODK vs AKBA Comparison

Compare KODK & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KODK
  • AKBA
  • Stock Information
  • Founded
  • KODK 1880
  • AKBA 2007
  • Country
  • KODK United States
  • AKBA United States
  • Employees
  • KODK N/A
  • AKBA N/A
  • Industry
  • KODK Business Services
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • KODK Consumer Discretionary
  • AKBA Health Care
  • Exchange
  • KODK Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • KODK 385.4M
  • AKBA 336.2M
  • IPO Year
  • KODK N/A
  • AKBA 2014
  • Fundamental
  • Price
  • KODK $5.37
  • AKBA $1.91
  • Analyst Decision
  • KODK
  • AKBA Strong Buy
  • Analyst Count
  • KODK 0
  • AKBA 2
  • Target Price
  • KODK N/A
  • AKBA $5.75
  • AVG Volume (30 Days)
  • KODK 456.1K
  • AKBA 2.3M
  • Earning Date
  • KODK 11-15-2024
  • AKBA 11-07-2024
  • Dividend Yield
  • KODK N/A
  • AKBA N/A
  • EPS Growth
  • KODK N/A
  • AKBA N/A
  • EPS
  • KODK 0.57
  • AKBA N/A
  • Revenue
  • KODK $1,060,000,000.00
  • AKBA $169,879,000.00
  • Revenue This Year
  • KODK N/A
  • AKBA N/A
  • Revenue Next Year
  • KODK N/A
  • AKBA $3.23
  • P/E Ratio
  • KODK $9.75
  • AKBA N/A
  • Revenue Growth
  • KODK N/A
  • AKBA N/A
  • 52 Week Low
  • KODK $3.33
  • AKBA $0.80
  • 52 Week High
  • KODK $6.18
  • AKBA $2.48
  • Technical
  • Relative Strength Index (RSI)
  • KODK 67.75
  • AKBA 68.47
  • Support Level
  • KODK $4.66
  • AKBA $1.30
  • Resistance Level
  • KODK $5.60
  • AKBA $2.01
  • Average True Range (ATR)
  • KODK 0.20
  • AKBA 0.12
  • MACD
  • KODK 0.08
  • AKBA 0.04
  • Stochastic Oscillator
  • KODK 84.34
  • AKBA 78.52

About KODK Eastman Kodak Company Common New

Eastman Kodak Co is a United States-based company. The company operates via several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: